-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] In recent years, under the environment of new medical reform and normalization of centralized procurement, the reshuffle of the pharmaceutical market has intensified.
Since 2022, a large number of pharmaceutical companies have stopped production and cancelled their certificates and no longer operate
.
On March 18, the Jiangxi Provincial Food and Drug Administration issued three consecutive announcements on the suspension of production of pharmaceutical companies
.
The announcement shows that these pharmaceutical companies have reported discontinued drugs to the Provincial Food and Drug Administration for their own reasons
.
On March 8, the Anhui Provincial Food and Drug Administration issued two information notices on the daily supervision and inspection of drug manufacturers
.
One of the unqualified Chinese herbal medicine companies has stopped production on its own
.
On March 4, the Sichuan Provincial Drug Administration issued an announcement stating that upon the application of the enterprise, the agency intends to cancel the "Drug Business License" of Yibin Hongfa Pharmaceutical Co.
,
Ltd.
On February 24, the Hebei Provincial Food and Drug Administration issued a notice on the cancellation of the "Drug Production License" of 35 companies, including 9 pharmaceutical excipient manufacturers, 5 Chinese medicine decoction pieces companies, 6 API companies, 4 companies.
1 tablet production company, 2 injection production pharmaceutical companies and many companies that produce preparations and medical gases have cancelled certificates
.
On February 22, the Shandong Provincial Food and Drug Administration announced that 21 pharmaceutical companies involved did not raise objections during the publicity period due to reasons such as the expiration of the validity period of the license and the failure to reissue the license.
Certificate"
.
On February 22, the Jiangsu Provincial Food and Drug Administration issued an announcement that from November 28 to 30, 2021, after a follow-up inspection of a pharmaceutical company, it was found that the company's hard capsules did not meet the relevant regulations for drug production quality management
.
According to relevant regulations, it was decided to suspend the production of hard capsules in this enterprise
.
On February 21, the Fujian Provincial Food and Drug Administration issued an announcement on the cancellation of the drug business license.
.
The three enterprises in the province did not apply for renewal of the "Drug Distribution License" when the validity period expired.
According to the regulations, the provincial bureau has gone through the cancellation procedures for the drug distribution licenses of these three enterprises in accordance with the law
.
On January 21, the Gansu Provincial Food and Drug Administration issued an announcement to cancel the "Drug Production License" of 10 pharmaceutical companies
.
The main reason for the cancellation is that the "Drug Production License" of the enterprise has expired and has not been renewed
.
At the end of January, the Guizhou Provincial Food and Drug Administration issued an announcement that a pharmaceutical company in Guizhou was ordered to immediately suspend the certification due to the unannounced inspection (special inspection of the centralized collection of glimepiride tablets) that found 2 serious defects, 2 major defects and other safety issues.
Manufacture and sales of Limemai tablets
.
At the same time, because this variety belongs to the second batch of domestically sourced varieties, the company's glimepiride tablets were also disqualified from the selection by the National Federation, and the company's participation in the country from January 29, 2022 to July 28, 2023 was suspended.
Eligibility for declaration of centralized procurement activities
.
In addition, in January, the Yunnan Provincial Food and Drug Administration also issued a number of announcements to cancel the "Drug Production License" of the enterprise
.
Most of these certificate-cancelling enterprises apply for cancellation of certificates on their own to terminate drug production
.
In addition to suspending production and canceling certificates, a large number of pharmaceutical companies have been punished for non-compliant operations since the beginning of this year
.
For example, recently, the Chongqing Municipal Food and Drug Administration released information on administrative law enforcement cases.
A pharmaceutical company in Chongqing was given a warning, confiscated illegal property, and confiscation of illegal gains for producing and selling inferior drugs.
On March 2, the Hubei Provincial Food and Drug Administration An administrative punishment information was released, and four pharmaceutical companies in Hubei were punished for producing and selling inferior drugs
.
From the perspective of the industry, in the pharmaceutical environment, the survival challenges of pharmaceutical companies have become more and more serious.
They not only need to face competition between enterprises, but also face stricter supervision.
The industry market reshuffle is inevitable, and pharmaceutical companies Only by actively making strategic layouts and operating in compliance can we go further
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
Since 2022, a large number of pharmaceutical companies have stopped production and cancelled their certificates and no longer operate
.
On March 18, the Jiangxi Provincial Food and Drug Administration issued three consecutive announcements on the suspension of production of pharmaceutical companies
.
The announcement shows that these pharmaceutical companies have reported discontinued drugs to the Provincial Food and Drug Administration for their own reasons
.
On March 8, the Anhui Provincial Food and Drug Administration issued two information notices on the daily supervision and inspection of drug manufacturers
.
One of the unqualified Chinese herbal medicine companies has stopped production on its own
.
On March 4, the Sichuan Provincial Drug Administration issued an announcement stating that upon the application of the enterprise, the agency intends to cancel the "Drug Business License" of Yibin Hongfa Pharmaceutical Co.
,
Ltd.
On February 24, the Hebei Provincial Food and Drug Administration issued a notice on the cancellation of the "Drug Production License" of 35 companies, including 9 pharmaceutical excipient manufacturers, 5 Chinese medicine decoction pieces companies, 6 API companies, 4 companies.
1 tablet production company, 2 injection production pharmaceutical companies and many companies that produce preparations and medical gases have cancelled certificates
.
On February 22, the Shandong Provincial Food and Drug Administration announced that 21 pharmaceutical companies involved did not raise objections during the publicity period due to reasons such as the expiration of the validity period of the license and the failure to reissue the license.
Certificate"
.
On February 22, the Jiangsu Provincial Food and Drug Administration issued an announcement that from November 28 to 30, 2021, after a follow-up inspection of a pharmaceutical company, it was found that the company's hard capsules did not meet the relevant regulations for drug production quality management
.
According to relevant regulations, it was decided to suspend the production of hard capsules in this enterprise
.
On February 21, the Fujian Provincial Food and Drug Administration issued an announcement on the cancellation of the drug business license.
.
The three enterprises in the province did not apply for renewal of the "Drug Distribution License" when the validity period expired.
According to the regulations, the provincial bureau has gone through the cancellation procedures for the drug distribution licenses of these three enterprises in accordance with the law
.
On January 21, the Gansu Provincial Food and Drug Administration issued an announcement to cancel the "Drug Production License" of 10 pharmaceutical companies
.
The main reason for the cancellation is that the "Drug Production License" of the enterprise has expired and has not been renewed
.
At the end of January, the Guizhou Provincial Food and Drug Administration issued an announcement that a pharmaceutical company in Guizhou was ordered to immediately suspend the certification due to the unannounced inspection (special inspection of the centralized collection of glimepiride tablets) that found 2 serious defects, 2 major defects and other safety issues.
Manufacture and sales of Limemai tablets
.
At the same time, because this variety belongs to the second batch of domestically sourced varieties, the company's glimepiride tablets were also disqualified from the selection by the National Federation, and the company's participation in the country from January 29, 2022 to July 28, 2023 was suspended.
Eligibility for declaration of centralized procurement activities
.
In addition, in January, the Yunnan Provincial Food and Drug Administration also issued a number of announcements to cancel the "Drug Production License" of the enterprise
.
Most of these certificate-cancelling enterprises apply for cancellation of certificates on their own to terminate drug production
.
In addition to suspending production and canceling certificates, a large number of pharmaceutical companies have been punished for non-compliant operations since the beginning of this year
.
For example, recently, the Chongqing Municipal Food and Drug Administration released information on administrative law enforcement cases.
A pharmaceutical company in Chongqing was given a warning, confiscated illegal property, and confiscation of illegal gains for producing and selling inferior drugs.
On March 2, the Hubei Provincial Food and Drug Administration An administrative punishment information was released, and four pharmaceutical companies in Hubei were punished for producing and selling inferior drugs
.
From the perspective of the industry, in the pharmaceutical environment, the survival challenges of pharmaceutical companies have become more and more serious.
They not only need to face competition between enterprises, but also face stricter supervision.
The industry market reshuffle is inevitable, and pharmaceutical companies Only by actively making strategic layouts and operating in compliance can we go further
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
